Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer

Clinical Cancer Research

Volumn 13, Issue 21, 2007, Pages 6293-6300

  Jin, Zhe ^a   Olaru, Alexandru ^a   Yang, Jian ^a   Sato, Fumiaki ^a   Cheng, Yulan ^a   Kan, Takatsugu ^a   Mori, Yuriko ^a   Mantzur, Carmit ^c   Paun, Bogdan ^a   Hamilton, James P ^a   Ito, Tetsuo ^a   Wang, Suna ^c   David, Stefan ^a   Agarwal, Rachana ^a   Beer, David G ^d   Abraham, John M ^a   Meltzer, Stephen J ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; MESSENGER RNA; TACHYKININ; TACHYKININ 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; BLOOD SAMPLING; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DNA METHYLATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT TRANSFORMATION; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SQUAMOUS CELL CARCINOMA; TACHYKININ 1 GENE;

BIOLOGICAL MARKERS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; DNA; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; HUMANS; METHYLATION; PROGNOSIS; PROMOTER REGIONS (GENETICS); RISK; RNA; SENSITIVITY AND SPECIFICITY; TACHYKININS; TUMOR MARKERS, BIOLOGICAL;

EID: 35948943898     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0818     Document Type: Article

References (27)

1. Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA. Tachykinins and tachykinin receptors: a growing family. Life Sci 2004;74:1445-63.
2. Walch AK, Zitzelsberger HF, Bruch J, et al. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am J Pathol 2000;156:555-66.
3. Koppert LB, Wijnhoven BP, van Dekken H, Tilanus HW, Dinjens WN. Themolecular biology of esophageal adenocarcinoma. J Surg Oncol 2005;92:169-90.
4. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001;1:157-62.
5. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
6. Fang MZ, Jin Z, Wang Y, et al. Promoter hypermethylation and inactivation of O(6)-methylguanine-DNA methyltransferase in esophageal squamous cell carcinomas and its reactivation in cell lines. Int J Oncol 2005;26:615-22.
7. Schulmann K, Sterian A, Berki A, et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's associated neoplastic progression and predicts progression risk. Oncogene 2005;24:4138-48.
8. Mori Y, Cai K, Cheng Y, et al. A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology 2006;131:797-808.
9. Stewart BW, Kleihues P, International Agency for Research on Cancer. World cancer report: oesophageal cancer. Lyon: IARC Press; 2003. p. 223-7.
10. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
11. Sobin LH, Wittekind Ch, and. International Union against Cancer. TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss; 2002.
12. Kawakami K, Brabender J, Lord RV, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000;92:1805-11.
13. Bender CM, Gonzalgo ML, Gonzales FA, Nguyen CT, Robertson KD, Jones PA. Roles of cell division and gene transcription in the methylation of CpG islands. Mol Cell Biol 1999;19:6690-8.
14. Shibata DM, Sato F, Mori Y, et al. Hypermethylation of HPP1 is associated with hMLH1 hypermethylation in gastric adenocarcinomas. Cancer Res 2002;62:5637-40.
15. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology1982;143:29-36.
16. Rudolph RE, Vaughan TL, Storer BE, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000;132:612-20.
17. Rozengurt E. Neuropeptides as growth factors for normal and cancerous cells. Trends Endocrinol Metab 2002;13:128-34.
18. Lieb K, Fiebich BL, Berger M, Bauer J, Schulze-Osthoff K. The neuropeptide substance P activates transcription factor NF-κB and κB-dependent gene expression in human astrocytoma cells. J Immunol 1997;159:4952-8.
19. Koon HW, Zhao D, Na X, Moyer MP, Pothoulakis C. Metalloproteinases and transforming growth factor-α mediate substance P-induced mitogen-activated protein kinase activation and proliferation in human colonocytes. J Biol Chem 2004;279:45519-27.
20. Manske JM, Hanson SE. Substance-P-mediated immunomodulation of tumor growth in a murine model. Neuroimmunomodulation 2005;12:201-10.
21. O'Connor TM, O'Connell J, O'Brien DI, Goode T, Bredin CP, Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol 2004;201:167-80.
22. Sharma P, Morales TG, Bhattacharyya A, et al. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. Am J Gastroenterol 1997;92:2012-6.
23. Weston AP, Krmpotich PT, Cherian R, Dixon A, Topalosvki M. Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: comparisonwith traditional long segment Barrett's esophagus. Am J Gastroenterol 1997;92:407-13.
24. Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RK. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999;116:277-85.
25. Hage M, Siersema PD, van Dekken H, Steyerberg EW, Dees J, Kuipers EJ. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol 2004;39:1175-9.
26. Brock MV, Gou M, Akiyama Y, et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 2003;9:2912-9.
27. Lee EJ, Lee BB, Kim JW, et al. Aberrant methylation of Fragile Histidine Triad gene is associated with poor prognosis in early stage esophageal squamous cell carcinoma. Eur J Cancer 2006;42:972-80.